Production of retroviral vectors for clinical use.

Retroviral vectors were the first viral vectors to enter clinical trials and continue to be attractive candidates for applications where integration of the transgene is required. While these vectors are versatile and are used widely in the research setting, large-scale production for human use poses various challenges to insure quality and high titer. Our vector production facility has produced and certified over 20 vectors for clinical use and continues to be challenged to adapt the ever-changing vector technology to a method of production that complies with Good Manufacturing Practice (GMP). We describe two manufacturing methods for producing material for Phase I/II clinical trials and suggest ways for investigators to adapt these methods for multiple applications.

[1]  R. Hawley.  Progress toward vector design for hematopoietic stem cell gene therapy. , 2001, Current gene therapy.

[2]  M. Hatzoglou,et al.  Efficient packaging of a specific VL30 retroelement by psi 2 cells which produce MoMLV recombinant retroviruses. , 1990, Human gene therapy.

[3]  W F Anderson,et al.  Improved methods of retroviral vector transduction and production for gene therapy. , 1994, Human gene therapy.

[4]  K. Cornetta,et al.  Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. , 2000, Human gene therapy.

[5]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[6]  T. Neff,et al.  Efficient gene transfer to hematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  S. Goff,et al.  A safe packaging line for gene transfer: separating viral genes on two different plasmids , 1988, Journal of virology.

[8]  S. Goff,et al.  Construction and use of a safe and efficient amphotropic packaging cell line. , 1988, Virology.

[9]  J. Ellis,et al.  Silencing of gene expression: implications for design of retrovirus vectors , 2001, Reviews in medical virology.

[10]  Armentano,et al.  Effect of internal viral sequences on the utility of retroviral vectors , 1987, Journal of virology.

[11]  J. Garcia,et al.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus , 1991, Journal of virology.

[12]  Y Takeuchi,et al.  High-titer packaging cells producing recombinant retroviruses resistant to human serum , 1995, Journal of virology.

[13]  R. Kuhn,et al.  Ross River Virus Glycoprotein-Pseudotyped Retroviruses and Stable Cell Lines for Their Production , 2001, Journal of Virology.

[14]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.

[15]  P. Kantoff,et al.  Gene expression in mice after high efficiency retroviral-mediated gene transfer. , 1985, Science.

[16]  I. Verma,et al.  Expression of a retrovirus encoding human HPRT in mice. , 1984, Science.

[17]  S. Orkin,et al.  Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo. , 1986, Proceedings of the National Academy of Sciences of the United States of America.